AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17068625
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia followed with postoperative intravenous analgesia (n=53)
Trial: 12941494
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention on generic drugs (verbal information and handout materials)
Trial: 10642232
Drug: Plasma N‐terminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma N‐terminal atrial natriuretic peptide >0.8 nmol/l
Trial: 9342765
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg LI 160/die
Trial: 9342765
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg imipramine/die
Trial: 3097159
Drug: Terfenadine (sufficient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (sufficient dose to cause maximum H1 receptor blockade)
Trial: 3097159
Drug: Histamine (acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (acting on the H1 receptor)
Trial: 28836154
Drug: Moderate hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypothermia (MH, n = 40, nasopharyngeal temperature 25 °C, rectal temperature 28 °C)
Trial: 28836154
Drug: Deep hypothermia
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep hypothermia (DH, n = 42, nasopharyngeal temperature 20 °C, rectal temperature 25 °C)
Trial: 23385272
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection plus physiotherapy
Trial: 23953523
Drug: Reduced-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose tacrolimus plus sirolimus (rTAC)
Trial: 23953523
Drug: Standard-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose tacrolimus and sirolimus (sTAC)
Trial: 17852727
Drug: Sequential retrieval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential retrieval order
Trial: 15871445
Drug: Celecoxib (Celebrex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (Celebrex 200 mg, Pfizer, Turkey)
Trial: 11789239
Drug: Rhinitis Spray
RxNorm normalized name: sodium chloride Nasal Spray [Rhinaris]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinitis Spray (RS)
Trial: 9169300
Drug: Haloperidol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (15 +/- 5 mg/day)
Trial: 9376336
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 +/- 2.5 mg/day)
Trial: 9376336
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 +/- 2.5 mg/day)
Trial: 9376336
Drug: Olanzapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (15 +/- 2.5 mg/day)
Trial: 8258676
Drug: Lisinopril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-40 mg/day)
Trial: 8258676
Drug: Nifedipine (30-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30-90 mg/day)
Trial: 3937666
Drug: Sustak-forte preparation
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustak-forte preparation (nitroglycerin with prolonged action)
Trial: 30675708
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg for 6 months
Trial: 27407100
Drug: Bevacizumab combination
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combination arm
Trial: 20495588
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg intravenous ketamine infusion diluted in 500 cc normal saline over a 5 hour period daily for one week and 300 mg of gabapentin 3 times daily.
Trial: 20495588
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion and 300 mg of gabapentin 3 times daily.
Trial: 8431046
Drug: Intercostal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal bupivacaine (0.5% bupivacaine, 360 mg/day)
Trial: 8431046
Drug: Intercostal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal saline solution (control group)
Trial: 8431046
Drug: Fixed-schedule intramuscular
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-schedule intramuscular buprenorphine
Trial: 29746227
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months)
Trial: 29746227
Drug: Dalteparin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6)
Trial: 26219538
Drug: FP-Sal novel
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP-Sal novel mDPI 100 μg-50 μg
Trial: 26219538
Drug: FP-Sal novel
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP-Sal novel mDPI 500 μg-50 μg
Trial: 26219538
Drug: Originator device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator device 100 μg-50 μg
Trial: 26219538
Drug: Originator device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator device 500 μg-50 μg
Trial: 23938309
Drug: Inhaled apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled apomorphine (mean dose 2.3 mg)
Trial: 23938309
Drug: Inhaled apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled apomorphine
Trial: 21074015
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 0.75 mg, two doses 12 hours apart during the preovulatory phase
Trial: 14651283
Drug: MTAD (2-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTAD (2-h treatment)
Trial: 26944385
Drug: midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam (0.15 mg/kg)
Trial: 26944385
Drug: tramadol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol (1 mg/kg)
Trial: 24300544
Drug: 12-week antiretroviral
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week antiretroviral therapy (ART)
Trial: 24300544
Drug: 48-week antiretroviral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 48-week antiretroviral therapy (ART)
Trial: 12584535
Drug: Varicella vaccine
RxNorm normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varicella vaccine (2-dose regimen)
Trial: 10586916
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with treatment failure infected with parasites carrying 16 repeat units
Trial: 1806475
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg, p.o.)
Trial: 1806475
Drug: GHRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH plus placebo (2 tablets, p.o.)
Trial: 6626904
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic prophylaxis after urodynamic investigation
Trial: 6626904
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (implied control)
Trial: 27206951
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg subcutaneously every 2 weeks (Q2W)
Trial: 22700527
Drug: Treatment on
RxNorm normalized name: Canesten Clotrimazole Thrush Treatment Once (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment on days 5 to 10 after hemorrhage
Trial: 22700527
Drug: Coiling treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coiling treatment on days 5 to 10 after hemorrhage
Trial: 22700527
Drug: Clipping treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clipping treatment on days 5 to 10 after hemorrhage
Trial: 22700527
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at 3 to 4 days after hemorrhage
Trial: 22700527
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at 5 to 10 days after hemorrhage
Trial: 22700527
Drug: Treatment >10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment >10 days after hemorrhage
Trial: 17268695
Drug: rHuEPO and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO and ACE inhibitors/ARBs
Trial: 17268695
Drug: rHuEPO with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO with other antihypertensives (calcium channel blockers or beta-adrenergic receptor blockers)
Trial: 12912816
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg single dose)
Trial: 11398172
Drug: Rectal examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal examination as initial screening test
Trial: 11398172
Drug: PSA screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA screening only (cut-off of 3.0 ng/ml)
Trial: 7767416
Drug: Rectal examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal examination
Trial: 2567372
Drug: Pentamidine mesylate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentamidine mesylate aerosol (4 mg/kg every 2 weeks for the first month then monthly) and zidovudine
Trial: 28110468
Drug: Increased breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased breakfast eating during treatment
Trial: 28110468
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change or decrease in daily eating frequency
Trial: 23255691
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of measles vaccine (study group)
Trial: 23255691
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of measles vaccine (control group)
Trial: 19050085
Drug: Pentastarch (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentastarch (500 mL - maximum 3 L or 28 mL x kg(‐1))
Trial: 16584102
Drug: Behavioural Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Family Therapy (BFT)
Trial: 16584102
Drug: Individual usual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual usual treatment
Trial: 1841044
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg twice daily for 10 days
Trial: 8904618
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg
Trial: 30280390
Drug: IV SNF472
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV SNF472 9 mg kg–1 in HD patients
Trial: 26624824
Drug: Metformin (≤2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (≤2000 mg/d)
Trial: 16581161
Drug: IC41 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC41 peptide vaccine
Trial: 16581161
Drug: Poly‐L‐arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly‐L‐arginine
Trial: 16581161
Drug: Poly‐l‐arginine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly‐l‐arginine alone
Trial: 3741530
Drug: suprofen sustained
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: suprofen sustained release 600 mg tablets
Trial: 3741530
Drug: indometacin sustained
RxNorm normalized name: indometacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indometacin sustained release 75 mg capsules
Trial: 27310329
Drug: QMF149 (indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device with activated charcoal
Trial: 27310329
Drug: QMF149 (indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device without activated charcoal
Trial: 27310329
Drug: Indacaterol maleate
RxNorm normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol maleate 300 μg inhaled via Breezhaler (BRZ) device
Trial: 27310329
Drug: Mouth rinsing
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth rinsing after inhalation
Trial: 24615306
Drug: 60-minute treatments
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-minute treatments 2 times weekly
Trial: 24615306
Drug: 60-minute treatments
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-minute treatments 3 times weekly
Trial: 24615306
Drug: 30-minute treatments
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-minute treatments
Trial: 23545865
Drug: Caudal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal dexmedetomidine (DEX) 0.5 μg/kg and bupivacaine 0.25%, 2.5 mg/kg
Trial: 23545865
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg/kg and fentanyl 1 μg/kg
Trial: 20152050
Drug: Ketorolac treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac treatment
Trial: 16633079
Drug: Prasugrel 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 40 mg LD/7.5 mg MD
Trial: 16633079
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg LD/15 mg MD
Trial: 16633079
Drug: Prasugrel 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 7.5 mg MD
Trial: 16633079
Drug: Prasugrel (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (both doses)
Trial: 12360154
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control with electrical cardioversion and antiarrhythmic drugs (amiodarone or other class III agents)
Trial: 12360154
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control with beta-blockers, digoxin, or pacemaker and AV nodal ablation
Trial: 7975851
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis B vaccine (ID-2)
Trial: 7975851
Drug: Intramuscular hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hepatitis B vaccine (IM-10)
Trial: 7975851
Drug: Intramuscular hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hepatitis B vaccine (IM-2)
Trial: 30922849
Drug: Rehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation treatment group (RTG)
Trial: 30096441
Drug: Medication reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reminder and symptom management intervention (automated system calling daily for medication reminders and weekly for symptom assessment)
Trial: 18728372
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin treatment (Control)
Trial: 18728372
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment (before and after)
Trial: 16188050
Drug: Aspirin-resistant group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-resistant group
Trial: 8563871
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg prednisolone daily
Trial: 8563871
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg prednisolone daily
Trial: 8563871
Drug: megadose pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: megadose pulsed steroid therapy (500 or 1000 mg hydrocortisone-21-sodium succinate or methylprednisolone intravenously once a day)
Trial: 2514981
Drug: High-dose L-deprenyl
RxNorm normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose L-deprenyl (up to 40 mg/day)
Trial: 2514981
Drug: Conventional doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doses of deprenyl (10 mg/day)
Trial: 335093
Drug: High-dose terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose terbutaline sulfate (1.5 mg)
Trial: 335093
Drug: Low-dose terbutaline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose terbutaline sulfate (0.75 mg)
Trial: 335093
Drug: Isoproterenol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (0.3 mg)
Trial: 27427555
Drug: Low-energy shock-wave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy shock-wave therapy (LESWT)
Trial: 27427555
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LESWT and BMSC transplantation
Trial: 26011919
Drug: Dieting (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dieting (reduced daily intake by 500 kilocalories)
Trial: 23065432
Drug: Extended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended daily hemodialysis (EHD)
Trial: 16624773
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg before operation and 80 microg/h for 48 h after operation
Trial: 16624773
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of normal saline before operation and 0.15% ropivacaine 2.0 ml/h for 48 h after operation
Trial: 11411461
Drug: D,L-fenfluramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L-fenfluramine (100 mg po)
Trial: 26866979
Drug: 7-day dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day dolutegravir functional monotherapy
Trial: 23357764
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil (1,500 mg)
Trial: 15781543
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 15% magnesium sulfate (12.4 mmol) plus 3 mg/kg lidocaine 0.5% diluted with saline to a total of 40 mL in group M
Trial: 15781543
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of saline plus 3 mg/kg lidocaine 0.5% diluted with saline to a total of 40 mL in group C
Trial: 14632754
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 (3.2 mg subcutaneous injections twice weekly for 12 weeks)
Trial: 14632754
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no injections for 12 weeks)
Trial: 8721025
Drug: rHuEPO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO at a dose of 150 IU/L
Trial: 8721025
Drug: rHuEPO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO at a dose of 250 IU/L
Trial: 8721025
Drug: rHuEPO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO at a dose of 400 IU/L
Trial: 8721025
Drug: Initial EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial EPO levels < 100 IU/L
Trial: 8721025
Drug: Initial EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial EPO levels > 100 IU/L
Trial: 1760823
Drug: Slow-release isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow-release isosorbide-5-mononitrate (IS-5-MN), 25 mg once daily
Trial: 1760823
Drug: Bupranolol, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupranolol, 50 mg once daily
Trial: 1760823
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IS-5-MN and bupranolol
Trial: 1760823
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (IS-5-MN and bupranolol)
Trial: 6123810
Drug: Clobazam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (20 mg or 30 mg per day)